Boardroom Alpha
Boardroom Alpha
ACN · Current Report (Form 8-K) · Filed January 28, 2026

Accenture PLC — Current Report (Form 8-K)

Form
8-K
Filed
January 28, 2026
Period
Jan 28, 2026
Ticker
ACN
Accession
0001467373-26-000005
Boardroom Alpha · Filing insights

Shareholders approved Amended SIP, increasing authorized shares by 7 million and extending the plan to 2035.

About Accenture PLC
Market cap
$123.9B
1Y TSR
−41.1%
3Y TSR
−15.2%
Board grade
C-
Sector
Technology
CEO
Julie Spellman Sweet
Last annual meeting: Jan 28, 2026 · View full Accenture PLC profile →
acn-20260128

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 28, 2026

pgxx_logo (1).jpg
Accenture plc
(Exact name of Registrant as specified in its charter)
Ireland001-3444898-0627530
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
1 Grand Canal Square
Grand Canal Harbour
Dublin 2, Ireland
(Address of principal executive offices)
Registrant’s telephone number, including area code: (353) (1) 646-2000
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Class A ordinary shares, par value $0.0000225 per shareACNNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐





Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
On January 28, 2026, Accenture plc (“Accenture”) held its 2026 annual general meeting of shareholders (the “Annual Meeting”). At the Annual Meeting, Accenture’s shareholders approved an amendment and restatement of the Amended and Restated Accenture plc 2010 Share Incentive Plan (as amended and restated, the “Amended SIP”), which had previously been approved by the Board of Directors of Accenture (the “Board”), subject to shareholder approval.
The Amended SIP is substantially the same as the prior Amended and Restated Accenture plc 2010 Share Incentive Plan, except that it has been amended to, among other things, (1) authorize an additional 7 million shares for issuance and (2) extend the term of the plan until December 12, 2035.
The material terms of the Amended SIP are described in Accenture’s definite proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on December 12, 2025 (the “Proxy Statement”), and the description of the plan included in the Proxy Statement under the section entitled “Proposal 3: Approval of Amended and Restated Accenture plc 2010 Share Incentive Plan” is incorporated herein by reference. The description of the Amended SIP is qualified in its entirety by reference to the full text of the Amended SIP, a copy of which is filed as Exhibit 10.1 hereto.

Item 5.07 Submission of Matters to a Vote of Security Holders
On January 28, 2026, Accenture held its Annual Meeting. Accenture’s shareholders approved each of the following proposals considered at the Annual Meeting. The following chart sets forth the number and percentage of votes cast for and against, and the number of abstention votes and broker non-votes, with respect to each proposal voted upon by Accenture’s shareholders (proposal numbers correspond to the proposal numbers used in the Proxy Statement):



ProposalsForAgainstAbstainedBroker
Non-Votes
1.
To appoint the following directors:
Martin Brudermüller
457,078,682 99.68 %1,485,942 0.32 %779,718 45,621,294 
Alan Jope
452,499,353 98.69 %6,003,912 1.31 %841,077 45,621,294 
Nancy McKinstry
418,613,377 91.28 %39,968,281 8.72 %762,684 45,621,294 
Jennifer Nason
455,764,738 99.39 %2,810,654 0.61 %768,950 45,621,294 
Paula A. Price
444,870,995 97.01 %13,712,447 2.99 %760,900 45,621,294 
Venkata (Murthy) Renduchintala
427,226,784 93.35 %30,411,642 6.65 %1,705,916 45,621,294 
Arun Sarin
411,051,436 89.68 %47,310,511 10.32 %982,395 45,621,294 
Julie Sweet
436,938,720 95.70 %19,654,511 4.30 %2,751,111 45,621,294 
Tracey T. Travis
454,040,541 99.01 %4,530,157 0.99 %773,644 45,621,294 
Masahiko Uotani457,090,277 99.68 %1,483,777 0.32 %770,288 45,621,294 
2.
To approve, in a non-binding vote, the compensation of Accenture’s named executive officers
400,199,445 87.73 %55,968,491 12.27 %3,176,406 45,621,294 
3.
To approve the Amended and Restated Accenture plc 2010 Share Incentive Plan to increase the number of shares available for issuance and make other amendments
440,871,284 96.27 %17,068,980 3.73 %1,404,078 45,621,294 
4.
To ratify, in a non-binding vote, the appointment of KPMG LLP (“KPMG”) as Accenture’s independent auditor and to authorize, in a binding vote, the Audit Committee of the Board to determine KPMG’s remuneration
460,457,192 91.32 %43,750,869 8.68 %757,575 — 
5.
To grant the Board the authority to issue shares under Irish law
497,072,673 98.58 %7,161,506 1.42 %731,457 — 
6.
To grant the Board the authority to opt-out of pre-emption rights under Irish law
476,907,934 94.61 %27,156,073 5.39 %901,629 — 
7.
To determine the price range at which Accenture can re-allot shares that it acquires as treasury shares under Irish law
500,380,458 99.26 %3,741,047 0.74 %844,131 — 



Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit No.Description
10.1
104The cover page from this Current Report on Form 8-K, formatted in Inline XBRL




Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

Date: January 28, 2026
ACCENTURE PLC
By:/s/ Joel Unruch
Name:  Joel Unruch
Title:General Counsel & Corporate Secretary



From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Accenture PLC (ACN)

Reference

Frequently asked questions

When did Accenture PLC file this 8-K?
Accenture PLC (ACN) filed this Current Report (Form 8-K) with the SEC on January 28, 2026. The accession number assigned by EDGAR is 0001467373-26-000005.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Shareholders approved Amended SIP, increasing authorized shares by 7 million and extending the plan to 2035. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Accenture PLC's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Accenture PLC has filed under CIK 1467373, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer